Hydrolysis of nipecotic acid phenyl esters.

J Pharm Sci

School of Pharmacy, Northeast Louisiana University, Monroe 71209.

Published: January 1990

The synthesis and anticonvulsant activity of nipecotic acid esters (1a-1f) have been previously reported. It was thought that these prodrug esters underwent hydrolytic conversion to 1 which inhibited GABA uptake, and that both 1 and an intact ester may have caused inhibition of GABA uptake which resulted in the anticonvulsant activity. There is, however, no stability data available to help evaluate these effects. We have determined degradation half-lives (t 1/2) of these phenyl esters dissolved in 10% serum solution or in pH 7.4 buffer (ionic strength = 0.25 adjusted with KCl) at 37 degrees C by monitoring the appearance of a phenolic compound for a period of 12 h with an HPLC method. Utilizing a published method, in vitro [14C]GABA uptake was measured. Results show that the hydrolysis rate in 10% serum solution was faster than that in buffer solution and that half-lives varied between 0.20 and 3.84 h. The uptake inhibition varied between 8.2 and 41.7% at 0.02 mM concentration, and percent GABA uptake inhibition correlated with log t 1/2 (r = -0.9827, p = 0.00045, based on a t test). Our data suggest that at concentrations ranging from 0.02 to 1 mM, inhibition of GABA uptake is mainly due to 1 formed after hydrolysis of 1a-1f.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.2600790115DOI Listing

Publication Analysis

Top Keywords

gaba uptake
16
nipecotic acid
8
phenyl esters
8
anticonvulsant activity
8
inhibition gaba
8
10% serum
8
serum solution
8
uptake inhibition
8
uptake
6
hydrolysis nipecotic
4

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Gothenburg, Sweden.

Background: Emerging evidence underscores the importance of neuroinflammation in the progression of Alzheimer's disease (AD) pathophysiology. Recent studies indicate the involvement of the inflammatory mechanisms both in amyloid- β (Aβ) and tau deposition in the brain. Nevertheless, due to the complexity of the immune responses and the intricate interplay between the peripheral and the central nervous systems, identifying biomarkers that reflect the brain´s inflammatory state in AD has been a challenge.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

University of Zurich, Zurich, Zurich, Switzerland.

Background: Type 2 diabetes mellitus (T2DM) is associated with a greater risk of Alzheimer's disease (AD). Synaptic impairment and protein aggregates have been reported in the brains of T2DM rodent models. Here, we assessed the changes in synaptic vesicle 2A (SV2A), amyloid-β, and tau that are featured pathologies in AD in T2DM rats in vivo.

View Article and Find Full Text PDF

Background: Microglial reactivity and neuroinflammation are crucial pathological processes in Alzheimer's Disease (AD). Several attempts to develop a treatment by supressing the immune response in AD have been made, yet these yielded very limited results. Recent studies suggest contrasting effects of microglial reactivity, indicating a biphasic response with both beneficial and deleterious effects at distinct stages of AD.

View Article and Find Full Text PDF

Impairment of Skeletal Muscle Contraction by Inhibitors of GABA Transporters.

Int J Mol Sci

November 2024

Kazan Institute of Biochemistry and Biophysics, Federal Research Center "Kazan Scientific Center of RAS", 2/31 Lobachevsky Street, P.O. Box 30, Kazan 420111, Russia.

γ-Aminobutyric acid (GABA) has a significant impact on the functioning of not only the central but also the peripheral part of the nervous system. Recently, various elements of the GABAergic signaling system have been discovered in the area of the neuromuscular junction of mammals. At the same time, the functional activity of membrane-bound GABA transporters (GATs) and their role in neuromuscular transmission have not been identified.

View Article and Find Full Text PDF

PET imaging of GABA receptors in pancreatic islets by [C]flumazenil.

EJNMMI Res

December 2024

Department of Medical Cell Biology, Department of Medical Sciences, Science for Life Laboratory, Uppsala University, Box 571, 75123, Uppsala, Sweden.

Background: Type 1 diabetes (T1D) is an autoimmune disease characterized by a progressive β-cell destruction. There are no clinically established methods for quantifying endocrine cells of the pancreas and current knowledge is almost exclusively based on autopsy material and functional measurements. Based on the expression of the γ-aminobutyric acid A receptors (GABARs) in pancreatic islets and the fact that GABAR agonists are being explored as treatment for T1D, we hypothesized that the positron emission tomography (PET) tracer [C]flumazenil ([C]FMZ) could serve as a marker of the endocrine mass of the pancreas.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!